Alder生物制药

ALDR NASDAQ
11.69
-0.76
-6.10%
交易中 15:18 06/18 EDT
开盘
12.53
昨收
12.45
最高
12.53
最低
11.33
成交量
135.31万
成交均量(3M)
88.38万
52周最高
20.87
52周最低
9.44
换手率
1.62%
市值
9.76亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Alder生物制药 ALDR股票价格,Alder生物制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
展开 >

最近浏览

名称
价格
涨跌幅